Hyodeoxycholic acidCAS# 83-49-8 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 83-49-8 | SDF | Download SDF |
PubChem ID | 23663448 | Appearance | White powder |
Formula | C24H40O4 | M.Wt | 392.56 |
Type of Compound | Steroids | Storage | Desiccate at -20°C |
Solubility | Soluble to 78 mg/mL (198.69 mM) in DMSO | ||
Chemical Name | sodium;(4R)-4-[(3R,5R,6S,10R,13R,17R)-3,6-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoate | ||
SMILES | CC(CCC(=O)[O-])C1CCC2C1(CCC3C2CC(C4C3(CCC(C4)O)C)O)C.[Na+] | ||
Standard InChIKey | DUYSCILLIVEITB-IHUGHQDSSA-M | ||
Standard InChI | InChI=1S/C24H40O4.Na/c1-14(4-7-22(27)28)17-5-6-18-16-13-21(26)20-12-15(25)8-10-24(20,3)19(16)9-11-23(17,18)2;/h14-21,25-26H,4-13H2,1-3H3,(H,27,28);/q;+1/p-1/t14-,15-,16?,17-,18?,19?,20+,21+,23-,24-;/m1./s1 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Hyodeoxycholic acid is a secondary bile acid formed in the small intestine by the gut flora, and acts as a TGR5 (GPCR19) agonist, with an EC50 of 31.6 µM in CHO cells. Hyodeoxycholic acid has hypolipidemic effect through regulation of FXR activation, it is a candidate for antiatherosclerotic drug, by significantly increasing the expression of genes involved in cholesterol efflux, such as Abca1, Abcg1,and Apoe,in a macrophage cell line. |
Targets | FXR | LDL | TGR5 | NO | FAS |
In vitro | Simultaneous determination of geniposide, baicalin, cholic acid and hyodeoxycholic acid in rat serum for the pharmacokinetic investigations by high performance liquid chromatography-tandem mass spectrometry.[Pubmed: 16750434]J Chromatogr B Analyt Technol Biomed Life Sci. 2006 Sep 14;842(1):22-7.
|
In vivo | Dietary hyodeoxycholic acid exerts hypolipidemic effects by reducing farnesoid X receptor antagonist bile acids in mouse enterohepatic tissues.[Pubmed: 25189147]Lipids. 2014 Oct;49(10):963-73.
Hyodeoxycholic acid improves HDL function and inhibits atherosclerotic lesion formation in LDLR-knockout mice.[Pubmed: 23752203]FASEB J. 2013 Sep;27(9):3805-17.We examined the effects of a natural secondary bile acid, Hyodeoxycholic acid (HDCA), on lipid metabolism and atherosclerosis in LDL receptor-null (LDLRKO) mice. |
Structure Identification | Molecules. 2013 Aug 30;18(9):10497-513.Synthesis and quantitative structure-property relationships of side chain-modified hyodeoxycholic acid derivatives.[Pubmed: 23999724]Bile acids have emerged as versatile signalling compounds of a complex network of nuclear and membrane receptors regulating various endocrine and paracrine functions. The elucidation of the interconnection between the biological pathways under the bile acid control and manifestations of hepatic and metabolic diseases have extended the scope of this class of steroids for in vivo investigations. |
Hyodeoxycholic acid Dilution Calculator
Hyodeoxycholic acid Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.5474 mL | 12.7369 mL | 25.4738 mL | 50.9476 mL | 63.6845 mL |
5 mM | 0.5095 mL | 2.5474 mL | 5.0948 mL | 10.1895 mL | 12.7369 mL |
10 mM | 0.2547 mL | 1.2737 mL | 2.5474 mL | 5.0948 mL | 6.3685 mL |
50 mM | 0.0509 mL | 0.2547 mL | 0.5095 mL | 1.019 mL | 1.2737 mL |
100 mM | 0.0255 mL | 0.1274 mL | 0.2547 mL | 0.5095 mL | 0.6368 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Stigmasterol
Catalog No.:BCN4376
CAS No.:83-48-7
- Beta-Sitosterol
Catalog No.:BCN1015
CAS No.:83-46-5
- Deoxycholic acid
Catalog No.:BCN1288
CAS No.:83-44-3
- Methylprednisolone
Catalog No.:BCC2256
CAS No.:83-43-2
- 1-Indanone
Catalog No.:BCN2245
CAS No.:83-33-0
- Phenindione
Catalog No.:BCC4699
CAS No.:83-12-5
- 4-Aminoantipyrine
Catalog No.:BCC8683
CAS No.:83-07-8
- Tolrestat
Catalog No.:BCC4084
CAS No.:82964-04-3
- 4-O-Galloylbergenin
Catalog No.:BCN6643
CAS No.:82958-45-0
- 11-O-Galloylbergenin
Catalog No.:BCN6637
CAS No.:82958-44-9
- Nafamostat Mesylate(FUT-175)
Catalog No.:BCC1228
CAS No.:82956-11-4
- CI 898 trihydrochloride
Catalog No.:BCC7248
CAS No.:82952-64-5
- 5-Amino-1-naphthol
Catalog No.:BCC8729
CAS No.:83-55-6
- Theobromine
Catalog No.:BCN1227
CAS No.:83-67-0
- 2-Hydroxy-1,4-naphoquinone
Catalog No.:BCN8398
CAS No.:83-72-7
- Ibogaine
Catalog No.:BCN4378
CAS No.:83-74-9
- Rotenone
Catalog No.:BCN5412
CAS No.:83-79-4
- Phytic acid
Catalog No.:BCN1282
CAS No.:83-86-3
- Riboflavine
Catalog No.:BCN2224
CAS No.:83-88-5
- Tabernanthine
Catalog No.:BCN6957
CAS No.:83-94-3
- Skimmianin
Catalog No.:BCN3468
CAS No.:83-95-4
- 4-Methoxycinnamic acid
Catalog No.:BCN5037
CAS No.:830-09-1
- Methyl 3-hydroxy-4,5-dimethoxybenzoate
Catalog No.:BCN1337
CAS No.:83011-43-2
- 1,6-Dioxaspiro[4.5]decan-2-methanol
Catalog No.:BCN4371
CAS No.:83015-88-7
Simultaneous determination of geniposide, baicalin, cholic acid and hyodeoxycholic acid in rat serum for the pharmacokinetic investigations by high performance liquid chromatography-tandem mass spectrometry.[Pubmed:16750434]
J Chromatogr B Analyt Technol Biomed Life Sci. 2006 Sep 14;842(1):22-7.
A simple, rapid, and specific analytical method for simultaneous determination of geniposide, baicalin, cholic acid and Hyodeoxycholic acid in 50 microL samples of rat serum was developed by high performance liquid chromatography-tandem mass spectrometry. The quantification of the target compounds was determined by multiple reaction monitoring (MRM) mode using electrospray ionization (ESI). The correlation coefficients of the calibration curves were better than 0.997. The intra- and inter-day accuracy, precision, and linear range had been investigated in detail. This method was subsequently applied to pharmacokinetic studies of geniposide, baicalin, cholic acid and Hyodeoxycholic acid in rats successfully.
Hyodeoxycholic acid improves HDL function and inhibits atherosclerotic lesion formation in LDLR-knockout mice.[Pubmed:23752203]
FASEB J. 2013 Sep;27(9):3805-17.
We examined the effects of a natural secondary bile acid, Hyodeoxycholic acid (HDCA), on lipid metabolism and atherosclerosis in LDL receptor-null (LDLRKO) mice. Female LDLRKO mice were maintained on a Western diet for 8 wk and then divided into 2 groups that received chow, or chow + 1.25% HDCA, diets for 15 wk. We observed that mice fed the HDCA diet were leaner and exhibited a 37% (P<0.05) decrease in fasting plasma glucose level. HDCA supplementation significantly decreased atherosclerotic lesion size at the aortic root region, the entire aorta, and the innominate artery by 44% (P<0.0001), 48% (P<0.01), and 94% (P<0.01), respectively, as compared with the chow group. Plasma VLDL/IDL/LDL cholesterol levels were significantly decreased, by 61% (P<0.05), in the HDCA group as compared with the chow diet group. HDCA supplementation decreased intestinal cholesterol absorption by 76% (P<0.0001) as compared with the chow group. Furthermore, HDL isolated from the HDCA group exhibited significantly increased ability to mediate cholesterol efflux ex vivo as compared with HDL of the chow diet group. In addition, HDCA significantly increased the expression of genes involved in cholesterol efflux, such as Abca1, Abcg1, and Apoe, in a macrophage cell line. Thus, HDCA is a candidate for antiatherosclerotic drug therapy.
Synthesis and quantitative structure-property relationships of side chain-modified hyodeoxycholic acid derivatives.[Pubmed:23999724]
Molecules. 2013 Aug 30;18(9):10497-513.
Bile acids have emerged as versatile signalling compounds of a complex network of nuclear and membrane receptors regulating various endocrine and paracrine functions. The elucidation of the interconnection between the biological pathways under the bile acid control and manifestations of hepatic and metabolic diseases have extended the scope of this class of steroids for in vivo investigations. In this framework, the design and synthesis of novel biliary derivatives able to modulate a specific receptor requires a deep understanding of both structure-activity and structure-property relationships of bile acids. In this paper, we report the preparation and the critical micellization concentration evaluation of a series of Hyodeoxycholic acid derivatives characterized by a diverse side chain length and by the presence of a methyl group at the alpha position with respect to the terminal carboxylic acid moiety. The data collected are instrumental to extend on a quantitative basis, the knowledge of the current structure-property relationships of bile acids and will be fruitful, in combination with models of receptor activity, to design and prioritize the synthesis of novel pharmacokinetically suitable ligands useful in the validation of bile acid-responsive receptors as therapeutic targets.